The inpatient economic and mortality impact of hepatocellular carcinoma from 2005 to 2009: Analysis of the US nationwide inpatient sample

Liver International

Volumn 33, Issue 8, 2013, Pages 1281-1286

  Mishra, Alita ^a,b   Otgonsuren, Munkhzul ^a   Venkatesan, Chapy ^b   Afendy, Mariam ^a   Erario, Madeline ^b   Younossi, Zobair M ^a,b  

^a BETTY AND GUY BEATTY CENTER FOR INTEGRATED RESEARCH   (United States)

^b INOVA FAIRFAX HOSPITAL   (United States)

Author keywords

HCC; Mortality; NIS; Resource; Utilization

Indexed keywords

ADULT; ARTICLE; DEMOGRAPHY; DISEASE SEVERITY; ECONOMICS; FEMALE; HOSPITAL PATIENT; HUMAN; LENGTH OF STAY; LIVER CELL CARCINOMA; LIVER TRANSPLANTATION; MAJOR CLINICAL STUDY; MALE; MORTALITY; UNITED STATES;

HCC; MORTALITY; NIS; RESOURCE; UTILIZATION;

CARCINOMA, HEPATOCELLULAR; FEMALE; HEALTH RESOURCES; HOSPITAL COSTS; HOSPITAL MORTALITY; HUMANS; INPATIENTS; LENGTH OF STAY; LINEAR MODELS; LIVER NEOPLASMS; LIVER TRANSPLANTATION; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; ODDS RATIO; PATIENT DISCHARGE; RISK FACTORS; TIME FACTORS; UNITED STATES;

EID: 84881547878     PISSN: 14783223     EISSN: 14783231     Source Type: Journal    
DOI: 10.1111/liv.12201     Document Type: Article

References (12)

1. Surveillance, Epidemiology, and End Results (SEER) Program. SEER database: incidence - SEER 9 Registries research data, Nov 2009 Sub (1973-2007). Bethesda, MD: National Cancer Institute, April 2010.
2. El-Serag HB. Hepatocellular Carcinoma. N Engl J Med 2012; 365: 1118-27.
3. Alazawi W, Cunningham M, Dearden J, Foster GR. Systematic review: outcome of compensated cirrhosis due to chronic hepatitis C infection. Aliment Pharmacol Ther 2010; 32: 344-55.
4. El-Serag HB, Mason AC. Rising incidence of hepatocellular carcinoma in the United States. N Engl J Med 1999; 340: 745-750.
5. El-Serag HB, Davila JA, Petersen NJ, et al. The continuing increase in the incidence of hepatocellular carcinoma in the United States: An update. Ann Intern Med 2003; 139: 817-23.
6. London WT, McGlynn KA. Liver cancer. In: Schottenfeld D, Fraumeni JF Jr, eds. Cancer Epidemiology and Prevention, 3rd edn. New York, NY: Oxford University Press, 2006; 1: 763-86.
7. Altekruse SF, McGlynn KA, Reichman ME. Hepatocellular carcinoma incidence, mortality, and survival trends in the united states from 1975 to 2005. J Clin Oncol 2009; 27: 1485-1491.
8. Wojciech B, Kotlyar DS, Forde KA. Non-viral causes of hepatocellular carcinoma. World J Gastroenterol 2010; 16: 3603-15.
9. Asselah T, Marcellin P. Interferon free therapy with direct acting antivirals for HCV. Liver Int 2013; 33: 93-104. DOI:10.1111/liv.12076.
10. Chou R, Hartung D, Rahman B, et al. Comparative effectiveness of antiviral treatment for Hepatitis C Virus infection in adults: a systematic review. Ann Intern Med 2013; 158: 114-123.
11. Younossi ZM, Stepanova M, Afendy M, et al. Changes in the prevalence of the most common causes of chronic liver diseases in the United States from 1988 to 2008. Clin Gastroenterol Hepatol. 2011; 9: 524-530.
12. Younossi ZM, Stepanova M. Hepatitis C virus infection, age, and Hispanic ethnicity increase mortality from liver cancer in the United States. Clin Gastroenterol Hepatol 2010; 8: 718-23.